European Oncolytic Virus Therapy Market 2019-2025

European Oncolytic Virus Therapy Market by Product (HSV-Based Oncolytic Viruses, Adenoviruses-Based Oncolytic Viruses, Vaccinia Virus-Based Oncolytic Viruses, Vesicular Stomatitis Virus-Based Oncolytic Viruses, Newcastle Disease Oncolytic Viruses, and Others), by Application (Prostate Cancer, Breast Cancer, Ovarian Cancer, Melanoma, and Others), and Forecast 2019-2025.

The European oncolytic virus therapy market is estimated to grow at a CAGR of around 14% during the forecast period. The market growth is attributed to the increasing number of clinical trials in the region coupled with the increasing prevalence of cancer in the region, thereby creating opportunities for the growth of the market. The market growth in Europe is attributed to the FDA approval for the commercialization of Imlygic in Europe in 2016. Moreover, there are numerous clinical trials that are still being conducted across the region.

Further, the European oncolytic virus therapy market is segmented on the basis of product and application. Based on the product, the market is segmented into HSV-based oncolytic viruses, adenoviruses-based oncolytic viruses, vaccinia virus-based oncolytic viruses, vesicular stomatitis virus-based oncolytic viruses, Newcastle disease oncolytic viruses, and other oncolytic viruses. HSV-based oncolytic virus therapy held the highest market share in 2018. Based on the application, the market is segmented into prostate cancer, breast cancer, ovarian cancer, melanoma, and others. In 2018, the melanoma application held the largest market share.

The report covers the analysis of several players operating in the European oncolytic virus therapy market. Some of the major players include Boehringer Ingelheim International GmbH, F. Hoffmann-La Roche Ltd., Medigene AG, Orca Therapeutics, OncoTheis, and others. In March 2018, Medigene AG started phase I/II clinical trial CD-TCR-001 (NCT03503968) with TCR-T cell immunotherapy MDG1011 for the treatment of various types of blood cancer. The MDG1011 is a company's first clinical TCR-T immunotherapy product candidate, with its first clinical trial with a TCR-T therapy in Germany. The phase I/II trial investigates the safety of MDG1011 to treat various types of blood cancer, which include acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and multiple myeloma (MM).

Research Methodology

The market study of the European oncolytic virus therapy market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. The team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors.

Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables the analyst to derive the closest possible figures without any major deviations in the actual number. The analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to the reports.

Secondary Sources Include:

• Financial reports of companies involved in the market.
• Authentic public databases such as the WHO, World Bank, and the National Institutes of Health.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report is intended for pharmaceutical and biopharmaceutical companies, healthcare organizations, research institutes and academics, investing companies, potential investors, government organizations and regulatory agencies, and other market participants for overall market analysis and competitive analysis. The report provides an in-depth analysis of market size, different products, and future market opportunities. The report will serve as a source for a 360-degree analysis of the market thoroughly delivering insights into the market for making better business decisions.

Market Segmentation:

1. European Oncolytic Virus Therapy Market Research and Analysis by Product
2. European Oncolytic Virus Therapy Market Research and Analysis by Application